Michele Milella, MD1, Maria Rosaria Ricciardi2*, Paola Bergamo, MS1*, Maria Cristina Scerpa, PhD3*, Jacopo Gervasoni, MS4*, Maria Teresa Petrucci, MD5, Sabina Chiaretti, MD6*, Simona Tavolaro, MS3*, Ludovica Ciuffreda, PhD1*, Samantha Decandia2*, Francesco Libotte2*, Stephen Lee Abrams7*, Linda S Steelman, BS., MS7*, Marina Konopleva, MD, PhD8, Francesco Cognetti, MD1*, Robert Foa9, Michael Andreeff, MD, PhD10, James McCubrey, PhD11 and Agostino Tafuri12
1Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy
2Division of Hematology, Department of Cellular Biotechnologies and Hematology, University La Sapienza, Roma, Italy
3Division of Hematology-Dept. of Cellular Biotechnologies and Hematology, University of Rome "La Sapienza", Rome, Italy
4Division of Hematology-Dept. of Cellular Biotechnologies and Hematology, University of Rome, Rome, Italy
5Hematology, University La Sapienza, Rome, Italy
6MILE Study Group, on Behalf of European LeukemiaNet (ELN, WP13), Munich, Germany
7Micro & Immun, East Carolina University, Greenville, NC
8Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
9Dept. of Cellular Biotechnologies & Hematology, University 'Sapienza', Rome, Italy
10Stem Cell Transplantation & Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX
11School of Medicine, East Carolina University, Greenville, NC
12Division of Hematology-Dept. of Cellular Biotechnologies and Hematology, University La Sapienza, Roma, Italy